New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization

@article{Viney2021NewDO,
  title={New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization},
  author={Kerri Viney and Nguyen Nhat Linh and Medea Gegia and Matteo Zignol and Philippe Glaziou and Nazir Ahmed Ismail and Tereza Kasaeva and Fuad Mirzayev},
  journal={European Respiratory Journal},
  year={2021},
  volume={57}
}
Multidrug-resistant tuberculosis (MDR-TB), defined as Mycobacterium tuberculosis with resistance to at least isoniazid and rifampicin [1], emerged as a threat to tuberculosis (TB) control worldwide in the 1990s [2]. This form of TB required the use of second-line drugs that were less effective, more toxic and costlier than first-line isoniazid- and rifampicin-based regimens. MDR-TB was one of the first infectious conditions to alert national authorities worldwide to the importance of… 

Is the new WHO definition of extensively drug-resistant tuberculosis easy to apply in practice?

TLDR
The new definition of extensively drug resistant tuberculosis poses some challenges that must be addressed in a coordinated fashion by researchers, TB control stakeholders and assay developers.

Impact of the revised definition of extensively drug-resistant tuberculosis

TLDR
The revised WHO definition of extensively drug-resistant (XDR) tuberculosis (TB) decreases the number of TB cases classified as such, and allows better focus on the most difficult to treat cases of TB, in France.

Editorial: Updates from the World Health Organization (WHO) on Global Treatment Recommendations for Drug-Susceptible and Multidrug-Resistant Tuberculosis

  • D. Parums
  • Medicine, Biology
    Medical science monitor : international medical journal of experimental and clinical research
  • 2021
TLDR
This Editorial aims to present the rationale for the 2020 and 2021 recommendations from the WHO for the management of drug-susceptible TB and MDR TB.

Anti-Mycobacterial Drug Resistance in Japan: How to Approach This Problem?

TLDR
AMR in NTM infections are rather serious in Japan, even when compared with challenges associated with DR-TB, and the appropriate use of drugs based on accurate drug susceptibility testing and the development of new compounds/regimens that are strongly bactericidal in a short-time course are highly expected.

Whole genome sequencing of multidrug-resistant Mycobacterium tuberculosis isolates collected in the Czech Republic, 2005–2020

TLDR
A first whole genome sequencing (WGS)-based analysis of multidrug resistant M. tuberculosis strains to explore the phylogenetic lineages diversity, drug resistance mechanisms, and ongoing transmission chains within the country highlights the utility of WGS as a high-resolution approach in the diagnosis, characterization of resistance patterns, and molecular-epidemiological analysis of resistant TB in the country.

Cost and availability of drugs and treatment regimens and availability of drug resistance testing for tuberculosis in Europe

TLDR
Tuberculosis control in Europe is limited by widespread lack of DST capacity to new and re-purposed drugs, lack of access to essential medications and high treatment cost for drug-resistant tuberculosis.

Availability and costs of medicines for the treatment of tuberculosis in Europe.

  • G. GüntherL. Guglielmetti Andrii Dudnyk
  • Medicine, Political Science
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • 2022

Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis

  • H. HatamiG. Sotgiu M. Nasiri
  • Medicine
    Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia
  • 2022
TLDR
In patients with MDR-TB receiving bedaquiline, culture conversion and treatment success rates are high even in cases of extensive resistance, and there was no evidence of publication bias.

Central carbon metabolism remodeling as a mechanism to develop drug tolerance and drug resistance in Mycobacterium tuberculosis

TLDR
This review summarizes the recent advances in the understanding of the metabolic adaptations used by Mtb persisters to achieve intrinsic drug tolerance and facilitate the emergence of drug resistance and presents metabolomics as a powerful tool to identify previously unexplored antibiotic targets and improved combinations of drug regimens against drug-resistant TB infection.

References

SHOWING 1-7 OF 7 REFERENCES

Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region

TLDR
The introduction of novel drugs into treatment must be accompanied by continuous phenotypic susceptibility testing and the analysis of genetic determinants of resistance, which reflects the complex nature of resistance acquisition.

Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons--Florida and New York, 1988-1991.

  • Medicine
    MMWR. Morbidity and mortality weekly report
  • 1991
TLDR
This report summarizes preliminary findings of the investigations and recommendations for prevention and control of MDR-TB outbreaks in four hospitals during 1990 and 1991.

Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention

TLDR
Currently known mechanisms of resistance include mutations within the atpE, Rv0678, and pepQ genes and the development of standardized drug susceptibility testing (DST) for bedaquiline is urgently needed.

Evolution of programmatic definitions used in tuberculosis prevention and care.

  • G. Migliori
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2018